REGN Cash & equivalents
Cash & equivalents at Regeneron Pharmaceuticals rose to $3.1B in fiscal 2025, the highest in the 5 years reported, from $2.5B in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 872589 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$3.1B
FY2024 $2.5B
HIGH$3.1B FY2025
LOW$2.5B FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $3.1B | +$630M |
| FY2024 | $2.5B | $-242M |
| FY2023 | $2.7B | $-376M |
| FY2022 | $3.1B | +$220M |
| FY2021 | $2.9B | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · REGN company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.